Research Article

Integrated Analysis of Ulcerative Colitis Revealed an Association between PHLPP2 and Immune Infiltration

Ting Li,1 Weidong Liu,2,3 Wenjia Hui,2,3 Tian Shi,2,3 Huan Liu,2,3 Yan Feng,2,3 and Feng Gao1,2,3

1Xinjiang Medical University, Urumqi, Xinjiang, China
2Department of Gastroenterology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
3Xinjiang Clinical Research Center for Digestive Diseases, China

Correspondence should be addressed to Feng Gao; xjgf0991@163.com

Received 10 January 2022; Revised 8 February 2022; Accepted 17 February 2022; Published 16 March 2022

Academic Editor: Yang Mi

Copyright © 2022 Ting Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ulcerative colitis (UC) is a progressive intestine inflammatory disease that is prone to recur. Herein, we utilize microarray technology and bioinformatics to reveal the underlying pathogenesis of UC and provide novel markers. Colonic biopsies were taken from eight UC patients and eight healthy controls. Three differentially expressed miRNAs (DEMs) and 264 differentially expressed genes (DEGs) were screened using mRNA and miRNA microarray. Most DEGs were significantly associated with immune response and were markedly enriched in the IL-17 signaling pathway. Among the target genes of DEMs, PHLPP2 overlapped with DEGs and the downregulation of PHLPP2 group was mainly involved in the epithelial–mesenchymal transition. PHLPP2 was downregulated in UC patients, which was validated in 5 GEO datasets and qRT-PCR. The ROC curve demonstrated that PHLPP2 has a perfect ability to distinguish UC patients from healthy controls. Moreover, PHLPP2 was low expression in patients with active UC. CIBERSORT algorithm indicated that the abundance of gamma delta T cells (P = 0.04), M0 macrophages (P = 0.01), and activated mast cells (P < 0.01) was significantly greater than that of the control group. The Spearman correlation analysis showed that PHLPP2 has a positive correlation with the proportion of activated NK cells (r = 0.62, P = 0.013) and Tregs (r = 0.55, P = 0.03), but negatively correlated with those of activated mast cells (r = −0.8, P < 0.01) and macrophages (r = −0.73, P < 0.01). These results indicate that PHLPP2 is associated with immune cells in the pathogenesis of UC, as well as provide new prospects and future directions of investigation.

1. Introduction

Ulcerative colitis (UC), a progressive and chronic inflammatory disease of the intestine, is one of the common inflammatory bowel diseases (IBDs) that cause huge burden on individuals and their family [1]. Genetic, environmental, and immunological factors contribute to UC pathogenesis [2, 3]. Despite major advances in therapeutic resources, the mechanisms underlying UC pathogenesis are multifaceted and have not been fully elucidated. Even with the newest treatments, remission rates are less than 50% and the emergence of drug resistance is inevitable [4]. Therefore, a comprehensive analysis of the pathogenesis and development of possible treatment strategies for UC are urgently required.

MicroRNAs (miRNAs) are a class of endogenous non-coding RNAs having a length of 19–25 nucleotides. miRNAs repress translation and promote mRNA degradation by interacting with the 3′ untranslated region of the target mRNA [5]. miRNAs are implicated in various pathological and physiological processes, such as cell proliferation, differentiation, apoptosis, and metabolism [6]. Recent studies have reported that miRNAs participate in the regulation of the intestinal mucosal barrier and mucosal immune system [7–9]. The aberrant expression of miRNAs has implications in UC development. A study of miRNAs can help explore the disease pathogenesis and identify new biomarkers.

The intestinal immune system is involved in UC progression [10]. During acute inflammation, patients present with heavy infiltration of inflammatory cells, including mast
cells, lymphocytes, macrophages, and dendritic cells, in the intestinal mucosa [11]. Recent evidence suggests that some miRNAs and mRNAs can regulate the cytokine gene expression in immune cells and have essential roles in regulating the immune response. MiR-29 downregulates the interleukin- (IL-) 12/23 expression or indirectly downregulates the IL-23 expression by inhibiting activated transcription factor 2, thereby inhibiting the activation of Th17 cells [12]. Therefore, the evaluation of different types of infiltrating immune cells is important for elucidating the underlying mechanisms of UC pathogenesis.

In the present study, crucial genes and miRNAs associated with UC pathogenesis were identified using the microarray technique, and their expression, function, and interaction were evaluated using bioinformatics analyses. We also validated key genes in multiple independent datasets. Furthermore, we investigated the association between the identified biomarker and immune cell infiltration in UC.

### 2. Materials and Methods

#### 2.1. Patients and Samples

The study was approved by the Ethics Committee of People’s Hospital of Xinjiang Uygur Autonomous Region (No. 2015110). The diagnosis of ulcerative colitis was established on the basis of clinical, endoscopic, and histological criteria. Eight patients with UC and eight age-, gender-, and ethnically matched normal controls (NC) were enrolled. Normal controls with infectious diseases, autoimmune disease, or cancers were excluded. A written informed consent was obtained from all the study participants. Colonic biopsies were collected through colonoscopy. In patients with UC, biopsies were performed at the sites of active inflammation in rectum. The biopsy tissue was derived from the rectum in normal controls. Tissues were snap frozen in liquid nitrogen and stored at −80°C. Total RNA was isolated using the mirVana™ isolation kit. miRNAs and mRNAs were screened using Affymetrix PrimeView™ Human Gene Expression Array and Agilent Human miRNA Microarray (Release 21.0, 8 × 60K), respectively. Data analysis was performed using Agilent GeneSpring software.

#### 2.2. Data Processing

Differentially expressed miRNAs (DEMiS) and differentially expressed genes (DEGs) between UC and normal tissues were identified using the “limma” package of R software. For the selection of DEMIs and DEGs, |log, fold change (FC)| > 1 was considered as the standard, and a P value of <0.05 was considered statistically significant. The DEGs and DEMIs were plotted using the “ggplot2” and “heatmap” packages in R version 4.1.2.

#### 2.3. GO, KEGG, and DO Analysis

To detect related signaling pathways and potential biological functions of the DEGs, gene ontology (GO) functional enrichment, KEGG pathway, and disease ontology analyses were performed using the “clusterProfiler” [13] and “DOSE” [14] R package. P value of <0.05 was considered as the criterion for statistical significance.

#### 2.4. Identification of the Key Genes

Databases, namely, miRTarBase (http://mi rtarbase.cuhk.edu.cn/php/index.php), miRDB (http://mirdb.org/), and TargetScan (http://www.targetscan.org/vert_72/), were used to predict the target genes of the DEMIs. Moreover, the intersection of the predicted target genes of DEMIs obtained using three databases was considered as the final target genes. The genes overlapping between the DEGs and final target genes were defined as the key genes.

#### 2.5. Gene Set Enrichment Analysis

Gene set enrichment analysis (GSEA) version 4.1.0 software was used to further analyze the potential function of the key genes with a permutation of 1000. The patients were categorized into “high” and “low” groups based on the median expression value of the key genes. Hallmark pathways were performed to determine the crucial functions of the key genes. A false discovery rate (FDR) < 0.25 and a nominal P value of <0.05 referred to the statistically significant difference.

#### 2.6. Validation of the Key Genes

The expression of key genes was further validated in GSE48958 [15], GSE73661 [16], GSE75214 [17], GSE87473 [18], and GSE92415 datasets. Additionally, the PHLPP2 expression in active and inactive patients was validated. The receiver operating characteristic (ROC) curve was plotted to assess the ability of the selected genes to distinguish between UC patients and controls.

#### 2.7. Evaluation of Immune Cell Infiltration

To compare immune cell abundance between UC patients and healthy samples, we used our dataset, which comprised eight UC samples and eight healthy control samples, for the assessment of tissue-infiltrated immune cells. The “CIBERSORT” algorithm was used to calculate the relative proportions of 22 types of infiltrating immune cells. Significant alterations in immune cells were identified using the Wilcoxon test at P < 0.05. Pearson correlation test was performed to investigate the correlation between the expression of key genes and disease ontology analyses were performed using the "clusterProfiler" [13] and "DOSE" [14] R package. P value of <0.05 was considered as the criterion for statistical significance.

### Table 1: Primer sequences

| Name       | Primer sequence                        |
|------------|----------------------------------------|
| PHLPP2     | F-CTTACATCTCTGTCCTTTGCACT R-GGTCGTTCAGTAGGTTCCAGTC |
| β-Actin (human) | F-CATGTACGTTGCTATCCAGGC R-CTCCCTTAATGTCACGCAGAT |

### Table 2: Clinical characteristics of the study population

|                          | Ulcerative colitis group | Healthy control group |
|--------------------------|--------------------------|-----------------------|
| Number of patients       | 8                        | 8                     |
| Mean age in years (±SD)  | 45.50 ± 11.58            | 45.63 ± 11.30         |
| Male sex                 | 50%                      | 50%                   |
| Ethnicity                |                          |                       |
| Han                      | 50%                      | 50%                   |
| Uygur                    | 50%                      | 50%                   |
Figure 1: Continued.
2.8. Quantitative RT-PCR. Total RNA was extracted from colonic tissues using Trizol (Invitrogen, USA) and quantified by a NanoDrop spectrophotometer (Thermo). cDNA was synthesized using a TIANscript RT kit (Tiangen, Beijing, China). Quantitative PCR amplification of cDNAs was performed on a LightCycler 480 Real-Time PCR System (Roche, USA). The mRNA level of genes was detected with SuperRealPreMix Plus kits (TIANGEN, Beijing, China). Expression levels of target genes were normalized to β-actin mRNA levels. The primers for the qRT-PCR are listed in Table 1.

3. Results

3.1. Screening of Differentially Expressed mRNAs and miRNAs. Table 2 presents the basic data of the participants in both groups. After analyzing with the criteria of adjusted \( P < 0.05 \) and \( |\log_{2}\text{FC}| > 1 \), three DEMIs and 264 DEGs were screened. The expression of these genes and miRNAs is shown in Figure 1. For specific DEMIS and DEGs, see Supplementary Tables 1 and 2.

3.2. Functional Enrichment Annotation. To further explore the functions of DEGs, we performed GO, KEGG, and DO analyses. The enriched GO annotation included immune response, extracellular matrix organization, and the regulation of inflammatory responses in the BP category.
Figure 2: Continued.

Gene ratio

Count

10
20
30

(p value)

BP

CC

MF

Gene ratio

Extracellular matrix structural constituent conferring tensile strength
Extracellular matrix structural constituent
Chemokine activity
Serine-type peptidase activity
Serine-type endopeptidase activity
Chemokine receptor binding
Cytokine activity
G protein-coupled receptor binding
Extracellular matrix structural constituent
Receptor ligand activity
Extracellular matrix component
Complex of collagen trimers
Collagen trimer
Blood microparticle
Basement membrane
Secretary granule lumen
Vesicle
Cytoplasmic vesicle lumen
Endoplasmic reticulum lumen
Collagen-containing extracellular matrix
Humoral immune response
Leukocyte chemotaxis
Leukocyte migration
Antimicrobial humoral response
Regulation of inflammatory response
Leukocyte chemotaxis
Granulocyte chemotaxis
Granulocyte migration

Disease Markers
Figure 2: Continued.
Endoplasmic reticulum lumen, collagen-containing extracellular matrix, and cytoplasmic vesicle lumen were included in the CC category. Receptor-ligand activity, endopeptidase activity, and extracellular matrix structural constituent were included in the MF category (Figure 2(a)). The KEGG pathway analysis mapped DEGs to the IL-17 signaling pathway and cytokine–cytokine receptor interaction pathway (Figure 2(b)). DO analysis suggested that these DEGs were closely linked with oral diseases (Figure 2(c)).

3.3. Identifying the Key Gene. Three databases (miRTarBase, TargetScan, and miRDB) were used to predict the target genes of the DEMIs. A total of 366 genes were obtained using the three databases and were considered as the final target genes. Only one gene, PHLPP2, intersected with DEGs (Figure 3(a)). The qPCR results revealed that PHLPP2 expression levels were significantly different between UC and healthy controls (Figure 3(b)). Analysis of the primary chip data showed that PHLPP2 was low expression in UC patients (Figure 3(c)). ROC curves indicated that PHLPP2 was a potential biomarker for distinguishing between UC patients and healthy controls in our patients’ cohort (Figure 3(d)).

3.4. GSEA. GSEA is a computational approach for detecting minor undetectable changes in the gene expression. GSEA
results indicated that the downregulation of the PHLPP2 group was mainly involved in the epithelial–mesenchymal transition (Figure 4).

3.5. External Validation of the Key Genes. To further validate the ability of PHLPP2 to distinguish between UC patients and controls, we examined the PHLPP2 expression in GEO datasets. PHLPP2 exhibited a significantly low expression in patients with UC from 5 datasets (GSE48958, GSE73661, GSE75214, GSE87473, and GSE92415) (Figure 5(a)). The ROC curve showed that PHLPP2 has an ability to distinguish between UC patients and healthy controls (Figure 5(b)). We also validated the PHLPP2 expression in active and inactive patients. The result shows that PHLPP2 was low expression in patients with active UC (GSE48958 and GSE75214) (Figure 6).

3.6. Immune Cell Infiltration Analysis. In our data, the abundance of gamma delta T cells ($p < 0.04$), M0 macrophages ($p < 0.01$), and activated mast cells ($p < 0.01$) was significantly greater than that of the control group, whereas activated NK cells ($p = 0.02$) and resting mast cells ($p < 0.01$) showed the reverse expression pattern (Figure 7(a)). The Spearman correlation analysis of the expression of PHLPP2 and immune cells showed that PHLPP2 is positively correlated with the proportion of activated NK cells (rho $= 0.62$, rho $= 0.62$, rho $= 0.62$, rho $= 0.62$, rho $= 0.62$).
Figure 4: Gene set enrichment analysis (GSEA) showed PHLPP2 low expression group was mainly related to epithelial-mesenchymal transition.

Figure 5: The expression level of PHLPP2 in the GEO database. (a) PHLPP2 was downregulated in UC patients in GSE48958, GSE73661, GSE75214, GSE87473, and GSE92415. (b) ROC curves reflecting the ability of PHLPP2 to distinguish between ulcerative colitis and healthy participants.
\( P = 0.013 \) and Tregs \((\rho = 0.55, P = 0.03)\), but negatively correlated with those of activated mast cells \((\rho = -0.8, P < 0.01)\) and M0 macrophages \((\rho = -0.73, P < 0.01)\) (Figures 7(b)–7(d)).

4. Discussion

UC is an autoimmune disease with a long-lasting course and a high recurrence rate. Patients with long-standing and/or extensive UC have an increased risk of developing colorectal cancer. With the advent of next-generation sequencing and gene chip technologies, researchers can identify DEMIs and DEGs responsible for the initiation and progression of diseases. Therefore, combining the expression data derived from the microarray and comprehensive bioinformatics analysis is a convenient approach. In this study, three miRNAs (miR-424-5p, miR-155-5p, and miR-192-5p) and 264 mRNAs were screened. Among the predicted target genes of the DEMIs, PHLPP2 intersected with DEGs. Therefore, we speculated that PHLPP2 is associated with the pathological mechanism of UC.

Previous studies have reported the significance of the miRNAs, which were identified in our study. Studies have reported a high expression of miR-155 in activated UC patients. Compared with the control group, a 1.22- to 2.33-fold level change of miR-155 was increased in UC samples [19, 20]. miR-155 could participate in the regulation of UC development by negatively regulating the TLR4 signaling pathway via targeting SHIP1 and SCOS1 [21]. Another mechanism of miR-155 involved in UC would be to modulate the Th17 cell differentiation and antigen presentation in dendritic cells [22]. Our results are consistent with those reported by Zahm et al. and Wu et al. who found decreased expression of miR-192 in the sigmoid colon of patients with UC [23, 24]. However, the specific mechanism of action of miR-192 is unclear. The impact of miR-424 on UC is indistinctive. miR-424 has been studied mostly in tumors and is aberrantly expressed in multiple cancers such as renal clear cell carcinomas [25], colon cancer [26], chronic leukemia [27], pancreatic cancer [28], and ovarian cancer [29]. Moreover, miR-424 plays a dual role as it acts both as a tumor suppressor [30, 31] and as a cancer promoter [28, 32]. In conclusion, microRNAs are implicated in intestinal inflammation and immunity in UC, providing a new direction for exploring the pathogenesis and target-specific therapy for UC.

PHLPP2 codes for homologous pleckstrin-homology-domain leucine-rich-repeat protein phosphatases. PHLPP2 expression is considerably downregulated in various human cancers [33–36]. It can negatively regulate AKT and PKC.
Figure 7: Continued.
signaling pathways by directly dephosphorylating AKT and PKC [37, 38]. Similarly, our data showed that PHLPP2 is downregulated in UC patients, and this finding can be verified from multiple GEO datasets. We compared PHLPP2 expression in active and inactive UC patients from the datasets and found that PHLPP2 is downregulated in patients with active UC compared with that in patients with inactive UC. These results corroborate the findings of Wen et al. [39] who found that PHLPP downregulation led to an increase in the Akt activity with the consequently reduced intestinal epithelial cell (IEC) apoptosis. The short-term downregulation of PHLPP showed positive impacts on protection against excessive death of IECs. However, long-lasting activation of PI3K/Akt signaling induces IEC proliferation [40, 41], which ultimately results in the development of colitis-associated cancer [42]. Recent studies have also found that the loss of PHLPP2 expression contributes to epithelial pyroptosis facilitating rapid progression of colitis [43]. Additionally, using GSEA, we found that the low-expressed PHLPP2 group was significantly enriched in the epithelial–mesenchymal transition- (EMT-) related pathway. As others have reported, PHLPP2 knockdown induces an increase in the levels of EMT markers [44]. Intestinal wall fibrosis is a common late complication of UC characterized by superficial inflammation of the rectum and colon, and its intestinal fibrosis is generally limited to the submucosa [45]. Increasing evidence has supported a role for EMT in the pathogenesis of IBD-associated intestinal fibrosis and potentially suggests the use of the EMT signature as a molecular tool to assess cancer risk in patients with active UC lesions [46, 47]. Taken together, we can infer that chronic and repeated inflammation-induced PHLPP loss contributes to the development of colitis-associated cancer.

Results of the KEGG analysis indicated that DEGs were mainly enriched in the IL-17 pathway. IL-17 is an important proinflammatory factor that promotes the infiltration of inflammatory cells in UC [48]. Genetic polymorphisms in the IL-23/IL-17 axis have a substantial impact on UC [49]. Several IL-17-targeted therapeutic agents have been developed and proven effective in most animal experiments in IBD in recent years [50]. The IL-17-targeted therapy may become a potential new therapy for UC in the future.

Innate and adaptive immunity are the two dominant factors that drive the progressive tissue damage in patients with UC [51]. Our results suggested that PHLPP2 is positively correlated with the proportion of activated NK cells and Tregs but negatively correlated with activated mast cells and M0 macrophages. CD4+ Tregs have immunosuppressive effects on the UC pathogenesis and have a major contribution in maintaining the intestinal immune homeostasis [52]. Tregs secrete IL-10 and TGF-β, which protect against colitis by suppressing the immune response [53]. A decrease in Tregs is related to UC pathogenesis [54], which can be because of the reduction in the quantity and function of Tregs, leading to the differentiation of CD4+ T cells to Th17 cells. The increased proportion of Th17 cells further promotes the secretion of inflammatory cytokines, which contribute to the progression of inflammatory responses [55]. Previous studies have reported that the proportion of macrophages increased with time in the mucosal, submucosal, and muscular layers of rats treated with 2,4,6-trinitrobenzene sulfonic acid and dextran sulfate sodium [56, 57]. Patients with UC exhibit severe infiltration and macrophage accumulation in the lamina propria of the colonic mucosa, which result in hypersensitivity to the stimulation by bacteria and their products and generation of abundant proinflammatory cytokines [58]. Targeted regulation of the
polarization state of macrophages is a potential target for UC remission. An increased number of mast cells were first identified by Nolte et al. in the colonic tissue of UC patients [59]. King et al. [60] subsequently found that during the active phase of UC, the number of mast cells was 6.3 times higher than its normal range in the inflammatory region, 19.5 times higher at the junction of diseased and normal tissue, and 15.8 times higher in the normal intestinal segment. Several studies have reported that mast cells have profound consequences in UC pathogenesis [61, 62]. Mast cells, after being stimulated by various factors, are activated and release various mediators and cytokines, which mediate the inflammatory response in the intestine [63, 64]. Therefore, the inhibition of the activation of enteric mast cells might be a promising therapy for UC [65]. Our results further indicated that PHLPP2 functioned in UC by regulating the immune cells.

5. Conclusions

PHLPP2 was identified as a candidate biomarker that may participate in UC pathogenesis. PHLPP2 was found to be correlated with the infiltration of immune cells, particularly Tregs, macrophages, and mast cells. The biological functions and pathways of the selected genes offer a holistic understanding of the underlying molecular mechanisms in UC. However, a more detailed investigation is required to validate the proposed mechanism.

Data Availability

The datasets used in this study can be obtained from the corresponding author upon reasonable request. The public data source is Gene Expression Omnibus database with the accession GSE48958, GSE73661, GSE75214, GSE87473, and GSE92415 (https://www.ncbi.nlm.nih.gov/geo/).

Ethical Approval

Ethical approval for this study was obtained from the Ethics Committee of People’s Hospital of Xinjiang Uygur Autonomous Region (Approval No. 2015110).

Consent

All patients provided signed informed consent in accordance with the Declaration of Helsinki.

Conflicts of Interest

No competing financial interests exist.

Acknowledgments

The results of this study were in part derived from the GEO databases (GSE48958, GSE73661, GSE75214, GSE87473, and GSE92415). We are grateful to the authors whose data is used in this study. This study was supported by the National Natural Science Foundation of China (No. 81560091) and Natural Science Foundation of Xinjiang Uygur Autonomous Region (No. 2021D01C200).

Supplementary Materials

Supplementary 1. Supplementary Table 1: differentially expressed miRNAs.

Supplementary 2. Supplementary Table 2: differentially expressed genes.

References

[1] G. G. Kaplan, “The global burden of IBD: from 2015 to 2025,” Nature Reviews. Gastroenterology & Hepatology, vol. 12, no. 12, pp. 720–727, 2015.
[2] B. Khor, A. Gardet, and R. J. Xavier, “Genetics and pathogenesis of inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 307–317, 2011.
[3] A. N. Ananthakrishnan, “Epidemiology and risk factors for IBD,” Nature Reviews. Gastroenterology & Hepatology, vol. 12, no. 4, pp. 205–217, 2015.
[4] N. V. Casteele, M. Ferrante, G. Van Assche et al., “Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease,” Gastroenterology, vol. 148, no. 7, pp. 1320–1329, 2015.
[5] D. J. Guarnieri and R. J. DiLeone, “MicroRNAs: a new class of gene regulators,” Annals of Medicine, vol. 40, no. 3, pp. 197–208, 2008.
[6] J. Raisch, A. Darfeuille-Michaud, and H. T. Nguyen, “Role of microRNAs in the immune system, inflammation and cancer,” World Journal of Gastroenterology, vol. 19, no. 20, pp. 2985–2996, 2013.
[7] C. He, Y. Shi, R. Wu et al., “miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD,” Gut, vol. 65, no. 12, pp. 1938–1950, 2016.
[8] X. Cheng, Z. Zhang, J. Su et al., “miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn’s disease,” Scientific Reports, vol. 5, no. 1, 2015.
[9] W. Wu, C. He, C. Liu et al., “miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD,” Gut, vol. 64, no. 11, pp. 1755–1764, 2015.
[10] M. F. Neurath, “Targeting immune cell circuits and trafficking in inflammatory bowel disease,” Nature Immunology, vol. 20, no. 8, pp. 970–979, 2019.
[11] B. Singh, S. Read, C. Asseman et al., “Control of intestinal inflammation by regulatory T cells,” Immunological Reviews, vol. 182, pp. 190–200, 2001.
[12] O. Brain, B. M. Owens, T. Pichulik et al., “The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release,” Immunity, vol. 39, no. 3, pp. 521–536, 2013.
[13] G. Yu, L. G. Wang, Y. Han, and Q. Y. He, “clusterProfiler: an R package for comparing biological themes among gene clusters,” OMICS, vol. 16, no. 5, pp. 284–287, 2012.
[14] G. Yu, L. G. Wang, G. R. Yan, and Q. Y. He, “DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis,” Bioinformatics, vol. 31, no. 4, pp. 608–609, 2015.
[15] J. Van der Goten, W. Vanhove, K. Lemaire et al., “Integrated miRNA and mRNA expression profiling in inflamed colon of
patients with ulcerative colitis, "PLoS One, vol. 9, no. 12, article e116117, 2014.

[16] I. Arijis, G. De Hertogh, B. Lemmens et al., “Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC,” Gut, vol. 67, no. 1, pp. 43–52, 2018.

[17] M. Vancamelleke, T. Vanuytsel, R. Farré et al., “Genetic and transcriptomic bases of intestinal epithelial barrier dysfunction in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 23, no. 10, pp. 1718–1729, 2017.

[18] K. Li, R. Strauss, J. Ouahed et al., “Molecular comparison of adult and pediatric ulcerative colitis indicates broad similarity of molecular pathways in disease tissue,” Journal of Pediatric Gastroenterology and Nutrition, vol. 67, no. 1, pp. 45–52, 2018.

[19] M. Min, L. Peng, Y. Yang, M. Guo, W. Wang, and G. Sun, “MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a,” Inflammatory Bowel Diseases, vol. 20, no. 4, pp. 652–659, 2014.

[20] S. Valmiki, V. Ahuja, and J. Paul, “MicroRNA exhibit altered expression in the inflamed colon mucosa of ulcerative colitis patients,” World Journal of Gastroenterology, vol. 23, no. 29, pp. 5324–5332, 2017.

[21] C. M. Ahmed, J. Larkin 3rd, and H. M. Johnson, “SOCS1 mimetics and antagonists: a complementary approach to positive and negative regulation of immune function,” Frontiers in Immunology, vol. 6, p. 183, 2015.

[22] R. Yao, Y. L. Ma, W. Liang et al., “MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1,” PloS One, vol. 7, no. 10, article e46082, 2012.

[23] A. M. Zahm, N. J. Hand, D. M. Tsoucas, C. L. le Guen, R. N. Baldassano, and J. R. Friedman, “Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon,” Journal of Crohn’s & Colitis, vol. 8, no. 9, pp. 1108–1117, 2014.

[24] F. Wu, M. Zikusoka, A. Trindade et al., “MicroRNAs Are Differentially Expressed in Ulcerative Colitis and Alter Expression of Macrophage Inflammatory Peptide-2α,” Gastroenterology, vol. 135, no. 5, pp. 1624–35.e24, 2008.

[25] T. F. Chow, Y. M. Youssef, E. Lianidou et al., “Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis,” Clinical Biochemistry, vol. 43, no. 1-2, pp. 150–158, 2010.

[26] Z. N. Ghonbalani, S. Shahmohamadnejad, P. Pasalar, and E. Khalili, “Hypermethylated miR-424 in colorectal cancer subsequently upregulates VEGF,” Journal of Gastrointestinal Cancer, 2021.

[27] C. P. Pallasch, M. Patz, Y. J. Park et al., “miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia,” Blood, vol. 114, no. 15, pp. 3255–3264, 2009.

[28] K. Wu, G. Hu, X. He et al., “MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer,” Pathology Oncology Research, vol. 19, no. 4, pp. 739–748, 2013.

[29] N. Dahiya, C. A. Sherman-Baust, T. L. Wang et al., “MicroRNA expression and identification of putative miRNA targets in ovarian cancer,” PLoS One, vol. 3, no. 6, article e2436, 2008.

[30] J. Xu, Y. Li, F. Wang et al., “Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer,” Oncogene, vol. 32, no. 8, pp. 976–987, 2013.

[31] S. Sarkar, B. K. Dey, and A. Dutta, “MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A,” Molecular Biology of the Cell, vol. 21, no. 13, pp. 2138–2149, 2010.

[32] D. Zhang, Y. Wang, Z. Shi et al., “Metabolic reprogramming of cancer-associated fibroblasts by IDH3a downregulation,” Cell Reports, vol. 10, no. 8, pp. 1335–1348, 2015.

[33] E. A. Rakha, A. R. Green, D. G. Powe, R. Roylance, and I. O. Ellis, “Chromosome 16 tumor-suppressor genes in breast cancer,” Genes, Chromosomes & Cancer, vol. 45, no. 6, pp. 527–535, 2006.

[34] S. D. Safford, D. Goyeau, A. J. Freermerman et al., “Fine mapping of Wilms’ tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases,” Annals of Surgical Oncology, vol. 10, no. 2, pp. 136–143, 2003.

[35] N. Töring, M. Borre, K. D. Sørensen, C. L. Andersen, C. Wiuf, and T. F. Ørntoft, “Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array,” British Journal of Cancer, vol. 96, no. 3, pp. 499–506, 2007.

[36] H. Tsuda, W. D. Zhang, Y. Shimosato et al., “Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 17, pp. 6791–6794, 1990.

[37] J. Liu, H. L. Weiss, P. Rychahou, L. N. Jackson, B. M. Evers, and T. Gao, “Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis,” Oncogene, vol. 28, no. 7, pp. 994–1004, 2009.

[38] J. Brognard and A. C. Newton, “PHLiPPing the switch on Akt and protein kinase C signaling,” Trends in Endocrinology and Metabolism, vol. 19, no. 6, pp. 223–230, 2008.

[39] Y. A. Wen, X. Li, T. Goresky, H. L. Weiss, T. A. Barrett, and T. Gao, “Loss of PHLPP protects against colitis by inhibiting intestinal epithelial cell apoptosis,” Biochim Biophys Acta, vol. 1852, no. 10, pp. 2013–2023, 2015.

[40] H. Sheng, J. Shao, C. M. Townsend, and B. M. Evers, “Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells,” Gut, vol. 52, no. 10, pp. 1472–1478, 2003.

[41] J. A. Engelman, J. Luo, and L. C. Cantley, “The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism,” Nature Reviews Genetics, vol. 7, no. 8, pp. 606–619, 2006.

[42] G. Lee, T. Goresky, E. Managlia et al., “Phosphoinositide 3-Kinase Signaling Mediates β-Catenin Activation in Intestinal Epithelial Stem and Progenitor Cells in Colitis,” Gastroenterology, vol. 139, no. 3, pp. 869–881.e9, 2010.

[43] D. F. Li, X. Chang, J. L. Zhao et al., “Colonic epithelial PHLPP2 deficiency promotes colonic epithelial pyroptosis by activating the NF-κB signaling pathway,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 5570731, 14 pages, 2021.

[44] X. Li, P. D. Stevens, J. Liu et al., “PHLPP is a negative regulator of RAFl, which reduces colorectal cancer cell motility and prevents tumor progression in mice,” Gastroenterology, vol. 146, no. 5, pp. 1301–1312.e10, 2014.

[45] S. Lovisa, G. Genovese, and S. Danese, “Role of epithelial-to-mesenchymal transition in inflammatory bowel disease,” Journal of Crohn’s & Colitis, vol. 13, no. 5, pp. 659–668, 2019.
[46] S. N. Flier, H. Tanjore, E. G. Kokkotou, H. Sugimoto, M. Zeisberg, and R. Kalluri, "Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis," *The Journal of Biological Chemistry*, vol. 285, no. 26, pp. 20202–20212, 2010.

[47] X. Zhao, J. Fan, F. Zhi et al., "Mobilization of epithelial mesenchymal transition genes distinguishes active from inactive lesional tissue in patients with ulcerative colitis," *Human Molecular Genetics*, vol. 24, no. 16, pp. 4615–4624, 2015.

[48] M. L. Rodríguez-Perálvarez, V. García-Sánchez, C. M. Villar-Pastor et al., "Role of serum cytokine profile in ulcerative colitis assessment," *Inflammatory Bowel Diseases*, vol. 18, no. 10, pp. 1864–1871, 2012.

[49] A. Geremia and D. P. Jewell, "The IL-23/IL-17 pathway in inflammatory bowel disease," *Expert Review of Gastroenterology & Hepatology*, vol. 6, no. 2, pp. 223–237, 2012.

[50] J. K. Yamamoto-Furusho and D. K. Podolsky, "Innate immunity in inflammatory bowel disease," *World Journal of Gastroenterology*, vol. 13, no. 42, pp. 5577–5580, 2007.

[51] A. O’Garra and P. Vieira, "Regulatory T cells and mechanisms of immune system control," *Nature Medicine*, vol. 10, no. 8, pp. 801–805, 2004.

[52] T. L. Whiteside, "What are regulatory T cells (Treg) regulating in cancer and why?," *Seminars in Cancer Biology*, vol. 22, no. 4, pp. 327–334, 2012.

[53] X. Sun, S. He, C. Lv et al., "Analysis of murine and human Treg subsets in inflammatory bowel disease," *Molecular Medicine Reports*, vol. 16, no. 3, pp. 2893–2898, 2017.

[54] J. Maul, C. Loddenkemper, P. Mundt et al., "Peripheral and intestinal regulatory CD4+ CD25 (high) T cells in inflammatory bowel disease," *Gastroenterology*, vol. 128, no. 7, pp. 1868–1878, 2005.

[55] X. Z. Shi, J. H. Winston, and S. K. Sarna, "Differential immune and genetic responses in rat models of Crohn’s colitis and ulcerative colitis," *American Journal of Physiology. Gastrointestinal and Liver Physiology*, vol. 300, no. 1, pp. G41–G51, 2011.

[56] L. S. Wang, C. T. Kuo, K. Stoner et al., "Dietary black raspberries modulate DNA methylation in dextran sodium sulfate (DSS)-induced ulcerative colitis," *Carcinogenesis*, vol. 34, no. 12, pp. 2842–2850, 2013.

[57] M. Zareie, P. K. Singh, E. J. Irvine, P. M. Sherman, D. McKay, and M. H. Perdue, "Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn’s disease," *The American Journal of Pathology*, vol. 158, no. 3, pp. 1101–1109, 2001.

[58] H. Nolte, N. Spjeldnaes, A. Kruse, and B. Windelborg, "Histamine release from gut mast cells from patients with inflammatory bowel diseases," *Gut*, vol. 31, no. 7, pp. 791–794, 1990.

[59] T. King, W. Biddle, P. Bhatia, J. Moore, and Miner PB Jr, "Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis," *Digestive Diseases and Sciences*, vol. 37, no. 4, pp. 490–495, 1992.

[60] G. Boecxkxstaens, "Mast cells and inflammatory bowel disease," *Current Opinion in Pharmacology*, vol. 25, pp. 45–49, 2015.

[61] S. H. He, "Key role of mast cells and their major secretory products in inflammatory bowel disease," *World Journal of Gastroenterology*, vol. 10, no. 3, pp. 309–318, 2004.